Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lactobacillus reuteri GMNL-89 composition for treating type II diabetes mellitus and use thereof

A technology of Lactobacillus reuteri and composition, applied in the field of Lactobacillus isolates, can solve problems such as no literature reports, and achieve the effects of improving high-density lipoprotein, improving insulin utilization, and reducing density lipoprotein

Inactive Publication Date: 2015-09-09
GENMONT BIOTECH
View PDF5 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, for the current model based on type 2 diabetes, whether probiotics can effectively improve the symptoms of type 2 diabetes has not been reported in the literature.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lactobacillus reuteri GMNL-89 composition for treating type II diabetes mellitus and use thereof
  • Lactobacillus reuteri GMNL-89 composition for treating type II diabetes mellitus and use thereof
  • Lactobacillus reuteri GMNL-89 composition for treating type II diabetes mellitus and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0135] Confirmation of Zoogenic Models

[0136] The fasting blood glucose levels of the rats in each group before the 7th week of the feeding period had no difference among the rats with type 2 diabetes. However, from the eighth week onwards, the blood glucose of the diabetic group, the group fed with high / low dose of live bacteria and the group of high dose of supernatant began to rise. In the serum group, the rising trend of fasting blood glucose was more moderate. The low-dose supernatant group was found to have the best protective effect on the animal model of type 2 diabetes induced by STZ+nicotinamide during the eight-week feeding period, and the results of this experiment also showed the same trend after ten weeks of feeding . The fasting insulin value started from the fourth week, and the insulin value of the diabetic group began to rise and showed the phenomenon of insulin compensation, which indicated that from the fourth week, the mice in the diabetic group had po...

Embodiment 2

[0138] Daily Food Intake Record

[0139] During the period of raising the mice, the food intake of the mice was recorded respectively, and the average value was taken. Because the difference in the intake of the mice may affect the body weight and affect the experimental results, it can be observed from the results in Table 2 that there is no statistical difference in the dietary intake of the mice in each group compared with the diabetic group. Therefore, we can speculate that the caloric intake of the mice should not be significantly different and will not affect the experimental results.

[0140] Table 2. Average food intake (g) during the raising of mice in each group

[0141]

Embodiment 3

[0143] Body weight and liver and kidney weight

[0144] In addition to the daily food intake records, we also recorded their weekly body weight changes. As can be seen from the results in Table 3, it can be observed that there is no statistical difference in the food intake of mice in each group compared with the diabetic group . At the tenth week, the rats were sacrificed for the experiment and their livers and kidneys were taken and their weights were measured. It was found that there was no statistically significant difference in the dietary intake of the rats in each group compared with the diabetic group (Table 4).

[0145] Table 3. Changes in body weight (g) of mice in each group during feeding

[0146]

[0147]

[0148] Table 4. Weights of liver and kidney organs of mice in each group (g)

[0149]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a new use of lactobacillus for treating type II diabetes mellitus, wherein the lactobacillus comprises viable bacteria, dead bacteria or a culture product supernatant of lactobacillus reuteri GMNL-89 having the preservation number of CCTCC M207154, and a pharmaceutically acceptable carrier. And the invention discloses the strain having the efficacies of resisting oxidative enzyme activity, resisting inflammation, lowering blood glucose, lowering triglycerides, lowering total cholesterols, reducing density lipoprotein, improving high-density lipoprotein, enhancing the utilization rate of insulin and the like in a type II diabetes mellitus animal mode.

Description

technical field [0001] The invention relates to the technical field of lactobacillus isolates, in particular to a composition of Lactobacillus reuteri GMNL-89 for treating type 2 diabetes and its application. Background technique [0002] Diabetes mellitus (Diabetes Mellitus) is a metabolic disease with multiple etiologies. It is a disease caused by widespread metabolic disorders caused by defects in insulin secretion or action. Diabetes is a disease characterized by persistent chronic hyperglycemia, which can also cause metabolic disorders such as protein, fat, water, and electrolytes in the body. [0003] Diabetes is clinically divided into two main categories: [0004] Type 1: Insulin-dependent diabetic mellitus (IDDM), which usually occurs in people under the age of 30. Therefore, it was called "juvenile-onset diabetes" in the past. In fact, it can occur at any age. Type 1 diabetes is an autoimmune disease in which the autoimmune system attacks and destroys the beta ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/747A61P3/10A61P25/00A61P13/12A61P29/00A61P3/06A61P9/00A61P27/02A61P1/16A23L1/29
Inventor 黄惠宇陈奕兴谢丰钦
Owner GENMONT BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com